Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CLS-TA · 2 trials · 7 indications
| Arm | Type | Description |
|---|---|---|
| 4 mg CLS-TA + IVT aflibercept | EXPERIMENTAL | Single unilateral, suprachoroidal injection of 40 mg/mL (4 mg in 100 µL) of CLS-TA following a 2 mg intravitreal injection of aflibercept |
| sham + IVT aflibercept | ACTIVE_COMPARATOR | Single unilateral, suprachoroidal sham procedure following a 2 mg intravitreal injection of aflibercept |
| 4 mg CLS-TA | EXPERIMENTAL | Single unilateral, suprachoroidal injection of 40 mg/mL (4 mg in 100 µL) of CLS-TA |
| 0.8 mg CLS-TA | EXPERIMENTAL | Single unilateral, suprachoroidal injection of 8 mg/mL (0.8 mg in 100 µL) of CLS-TA |
| Name | Type | Description |
|---|---|---|
| 4 mg CLS-TA | DRUG | 40 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension) |
| Sham | DRUG | suprachoroidal sham procedure |
| IVT aflibercept | DRUG | 2 mg intravitreal injection of aflibercept |
| 0.8 mg CLS-TA | DRUG | 8 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension) |
Inclusion Criteria: * diagnosis of macular edema following RVO * History of ME ≤ 12 months * 20-70 letters inclusive BCVA using ETDRS Exclusion Criteria: * has had an IVT injection of anti-VEGF for RVO in the study eye * has had a corticosteroid injection in the past 3 months in the study eye * a...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| EyePoint, Inc. | EYPT | 2 | PHASE3 | EYP-1901, Aflibercept |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE3 | Aflibercept |
| Oculis Holding AG | OCS | 2 | PHASE3 | Dexamethasone, Vehicle |
| AbbVie, Inc. | ABBV | 3 | PHASE2 | ABBV-RGX-314 Dose 1, Steroid, Aflibercept |
| Outlook Therapeutics, Inc. | OTLK | 1 | PHASE3 | bevacizumab |
| 4D Molecular Therapeutics, Inc. | FDMT | 1 | PHASE2 | 4D-150 IVT, Aflibercept IVT |
| Alvotech | ALVO | 1 | PHASE3 | AVT29, Eylea HD |
| Kiora Pharmaceuticals, Inc. | KPRX | 1 | PHASE2 | KIO-104 |
| REGENXBIO, Inc. | RGNX | 1 | PHASE2 | RGX-314 Dose 1, RGX-314 Dose 2, Aflibercept |
| Ocugen Inc | OCGN | 1 | PHASE1 | OCU200 |
| Adverum Biotechnologies, Inc. | ADVM | 1 | - | ADVM-022 |
CLS-TA is an investigational small molecule being developed by Clearside Biomedical for the treatment of macular edema and uveitis. It is administered by suprachoroidal injection. CLS-TA is currently in Phase 2 clinical development and is not yet approved by the FDA.
CLS-TA is a formulation of triamcinolone acetonide, a corticosteroid that works by reducing inflammation. It is delivered via suprachoroidal injection to treat conditions like macular edema and uveitis. The drug is being studied for its ability to manage inflammation in the back of the eye.
CLS-TA is being developed by Clearside Biomedical, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol CLSD. The company is focused on developing treatments for ophthalmic diseases using its proprietary suprachoroidal injection platform.
CLS-TA is in Phase 2 clinical development. It has completed two Phase 2 trials, one in patients with macular edema following non-infectious uveitis and another in patients with macular edema following retinal vein occlusion. CLS-TA is investigational and has not received FDA approval.
CLS-TA has completed two Phase 2 clinical trials. The first, NCT02255032, studied suprachoroidal injection of triamcinolone acetonide in subjects with macular edema following non-infectious uveitis. The second, NCT02303184, evaluated the same injection combined with IVT aflibercept in subjects with macular edema following retinal vein occlusion.
CLS-TA is a proprietary formulation of triamcinolone acetonide, a corticosteroid. It is designed for suprachoroidal injection, a targeted delivery method to the back of the eye. While the active ingredient is triamcinolone acetonide, CLS-TA refers specifically to Clearside Biomedical's investigational product.